Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $171,445 | 83 | 58.3% |
| Consulting Fee | $64,620 | 23 | 22.0% |
| Food and Beverage | $30,065 | 618 | 10.2% |
| Travel and Lodging | $25,799 | 86 | 8.8% |
| Honoraria | $1,500 | 1 | 0.5% |
| Education | $476.81 | 8 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $120,103 | 263 | $0 (2024) |
| Janssen Products, LP | $76,831 | 103 | $0 (2023) |
| ViiV Healthcare Company | $50,446 | 176 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $20,047 | 49 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $12,268 | 21 | $0 (2017) |
| Theratechnologies Inc. | $10,067 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $2,854 | 162 | $0 (2023) |
| ABBVIE INC. | $729.76 | 13 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $255.38 | 3 | $0 (2024) |
| Napo Pharmaceuticals Inc | $165.68 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,632 | 57 | ViiV Healthcare Company ($1,771) |
| 2023 | $4,239 | 68 | Gilead Sciences, Inc. ($1,798) |
| 2022 | $18,122 | 81 | ViiV Healthcare Company ($13,003) |
| 2021 | $13,540 | 122 | ViiV Healthcare Company ($8,800) |
| 2020 | $17,890 | 78 | Gilead Sciences, Inc. ($8,900) |
| 2019 | $16,036 | 68 | ViiV Healthcare Company ($12,699) |
| 2018 | $81,116 | 144 | Gilead Sciences, Inc. ($37,544) |
| 2017 | $139,332 | 201 | Gilead Sciences Inc ($65,844) |
All Payment Transactions
819 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: HIV | ||||||
| 12/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.55 | General |
| 12/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: HIV | ||||||
| 12/11/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTIBIOTIC | ||||||
| 11/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $99.31 | General |
| 11/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: HIV | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $54.03 | General |
| 10/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.22 | General |
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $149.89 | General |
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.09 | General |
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.50 | General |
| 10/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTIBIOTIC | ||||||
| 10/03/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $130.32 | General |
| Category: HIV | ||||||
| 09/27/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: HIV | ||||||
| 09/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.80 | General |
| 09/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $5.38 | General |
| Category: ANTIBIOTIC | ||||||
| 08/29/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $107.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/21/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: HIV | ||||||
| 08/15/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HCV | ||||||
| 08/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $122.91 | General |
| Category: HIV | ||||||
| 08/12/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HIV | ||||||
| 08/01/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: HIV | ||||||
| 07/23/2024 | Theratechnologies Inc. | — | Food and Beverage | In-kind items and services | $77.46 | General |
| 07/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: HIV | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 394 | 521 | $316,522 | $39,596 |
| 2022 | 6 | 298 | 419 | $235,455 | $32,305 |
| 2021 | 6 | 285 | 406 | $224,307 | $31,745 |
| 2020 | 9 | 416 | 558 | $261,097 | $37,258 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 100 | 122 | $65,270 | $8,968 | 13.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 56 | $80,632 | $8,899 | 11.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 90 | $45,450 | $6,527 | 14.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 97 | 132 | $46,860 | $6,191 | 13.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 40 | $45,910 | $4,779 | 10.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 44 | 81 | $32,400 | $4,232 | 13.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 64 | 90 | $51,750 | $8,700 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 66 | 104 | $52,520 | $7,924 | 15.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 73 | 103 | $55,535 | $6,927 | 12.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 38 | 38 | $43,610 | $4,654 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 45 | 72 | $28,800 | $3,472 | 12.1% |
| 99448 | Telephone or internet assessment with verbal and written report by consulting physician, 21-30 minutes | Facility | 2022 | 12 | 12 | $3,240 | $628.55 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 66 | 99 | $54,605 | $9,404 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 62 | 90 | $44,910 | $7,045 | 15.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 50 | 94 | $37,600 | $5,076 | 13.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 71 | $36,880 | $4,798 | 13.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 26 | $29,472 | $3,270 | 11.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 26 | 26 | $20,840 | $2,151 | 10.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 75 | 120 | $59,400 | $11,078 | 18.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 74 | 85 | $38,250 | $5,534 | 14.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 43 | 43 | $49,189 | $5,272 | 10.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 66 | $29,370 | $3,829 | 13.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 56 | 97 | $36,400 | $3,543 | 9.7% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 30 | 30 | $24,138 | $2,894 | 12.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 39 | 49 | $11,865 | $2,193 | 18.5% |
About Dr. Peter Alpert, MD
Dr. Peter Alpert, MD is a Infectious Disease healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104916907.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Alpert, MD has received a total of $293,906 in payments from pharmaceutical and medical device companies, with $3,632 received in 2024. These payments were reported across 819 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($171,445).
As a Medicare-enrolled provider, Alpert has provided services to 1,393 Medicare beneficiaries, totaling 1,904 services with total Medicare billing of $140,904. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Bronx, NY
- Active Since 10/13/2006
- Last Updated 12/13/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1104916907
Products in Payments
- PREZCOBIX (Drug) $30,994
- Genvoya (Drug) $29,972
- Biktarvy (Drug) $25,503
- ISENTRESS (Drug) $19,746
- DOVATO (Drug) $19,637
- Truvada (Drug) $12,136
- Descovy (Drug) $10,563
- Symtuza (Drug) $6,040
- EGRIFTA (Drug) $4,997
- SYMTUZA (Drug) $4,972
- Odefsey (Drug) $4,590
- RUKOBIA (Drug) $3,385
- JULUCA (Drug) $850.43
- EVOTAZ (Drug) $500.00
- CABENUVA (Biological) $327.67
- NUZYRA (Drug) $255.38
- Epclusa (Drug) $250.00
- ZEPATIER (Drug) $249.56
- MAVYRET (Drug) $248.81
- TROGARZO (Drug) $212.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Bronx
Mr. Norbert Brau, M.d, M.D
Infectious Disease — Payments: $180,229
Hernan Valdez, Md, MD
Infectious Disease — Payments: $36,939
Barry Zingman, Md, MD
Infectious Disease — Payments: $34,198
Arturo Casadevall, Md, MD
Infectious Disease — Payments: $29,572
Dial Hewlett, Md, MD
Infectious Disease — Payments: $19,196
Julio Quintanilla, M.d, M.D
Infectious Disease — Payments: $16,077